Development of phage lysin LysA2 for use in improved purity assays for live biotherapeutic products

Viruses

Volumn 7, Issue 12, 2015, Pages 6675-6688

  Dreher Lesnick, Sheila M ^a   Schreier, Jeremy E ^a   Stibitz, Scott ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Endolysin; Lactobacillus; Live biotherapeutic product; LysA2; Phage lysins; Probiotics; Purity assay

Indexed keywords

LYPRESSIN; PROBIOTIC AGENT; PROTEINASE; RECOMBINANT PROTEIN; VIRAL PROTEIN;

ANTIGEN BINDING CELL; ARTICLE; BACTERIAL KINETICS; BIFIDOBACTERIUM; BIOLOGICAL THERAPY; CELL VIABILITY; IMMUNOSUPPRESSIVE TREATMENT; LACTOBACILLUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PURIFICATION; DRUG CONTAMINATION; DRUG EFFECTS; ESCHERICHIA COLI; GENETICS; HUMAN; METABOLISM; MICROBIAL VIABILITY; PHARMACEUTICS; QUALITY CONTROL; STANDARDS; STAPHYLOCOCCUS AUREUS;

DRUG CONTAMINATION; ENDOPEPTIDASES; ESCHERICHIA COLI; HUMANS; LACTOBACILLUS; MICROBIAL VIABILITY; PROBIOTICS; QUALITY CONTROL; RECOMBINANT PROTEINS; STAPHYLOCOCCUS AUREUS; TECHNOLOGY, PHARMACEUTICAL; VIRAL PROTEINS;

EID: 84950144419     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7122965     Document Type: Article

References (28)

1. Clinicaltrials. Gov. Available online: https://clinicaltrials. gov/(accessed on 25 September 2015).
2. The federal food, drug, and cosmetic act. In 21-Food and Drugs, 2010 ed.; U. S. Government Printing Office: Washington, DC, USA, 2010. Available online: http://www. gpo. gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapII. htm (accessed on 25 September 2015).
3. Guidance for Industry Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information. Available online: http://www. fda. gov/downloads/BiologicsBloodVaccines/Guidance-ComplianceRegulatoryInformation/Guidances/General/UCM292704. pdf (accessed on 25 September 2015).
4. 21 cfr 312. 22-General Principles of the Ind Submission. Available online: http://www. gpo. gov/fdsys/pkg/CFR-2011-title21-vol5/xml/CFR-2011-title21-vol5-sec312-22. xml (accessed on 25 September 2015).
5. Nelson, D. C.; Schmelcher, M.; Rodriguez-Rubio, L.; Klumpp, J.; Pritchard, D. G.; Dong, S.; Donovan, D. M. Endolysins as antimicrobials. Adv. Virus Res. 2012, 83, 299-365. [PubMed]
6. Fischetti, V. A. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol. 2008, 11, 393-400. [CrossRef] [PubMed]
7. Ribelles, P.; Rodriguez, I.; Suarez, J. E. Lysa2, the Lactobacillus casei bacteriophage A2 lysin is an endopeptidase active on a wide spectrum of lactic acid bacteria. Appl. Microbiol. Biotechnol. 2012, 94, 101-110. [CrossRef] [PubMed]
8. Loessner, M. J. Bacteriophage endolysins-Current state of research and applications. Curr. Opin. Microbiol. 2005, 8, 480-487. [CrossRef] [PubMed]
9. Schuch, R.; Fischetti, V. A.; Nelson, D. C. A genetic screen to identify bacteriophage lysins. Methods Mol. Biol. 2009, 502, 307-319. [PubMed]
10. Vallabhaneni, S.; Walker, T. A.; Lockhart, S. R.; Ng, D.; Chiller, T.; Melchreit, R.; Brandt, M. E.; Smith, R. M. Centers for Disease Control and Prevention. Notes from the field: Fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement-Connecticut, 2014. Morb. Mortal. Wkly. Rep. 2015, 64, 155-156.
11. Pharmacopeia, U. S. 61-Microbiological examination of nonsterile products: Microbial enumeration tests. In Usp Pharmacists' Pharmacopeia; United States Pharmacopeial Convention: Rockville, MD, USA, 2009; pp. S3/43-S43/47.
12. Pharmacopeia, U. S. 62-Microbiological examination of nonsterile products: Tests for specified microorganims. In Usp Pharmacists' Pharmacopeia; United States Pharmacopeial Convention: Rockville, MD, USA, 2009; pp. S3/47-S43/51.
13. Schmelcher, M.; Donovan, D. M.; Loessner, M. J. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012, 7, 1147-1171. [CrossRef] [PubMed]
14. Schmelcher, M.; Waldherr, F.; Loessner, M. J. Listeria bacteriophage peptidoglycan hydrolases feature high thermoresistance and reveal increased activity after divalent metal cation substitution. Appl. Microbiol. Biotechnol. 2012, 93, 633-643. [CrossRef] [PubMed]
15. Becker, S. C.; Foster-Frey, J.; Stodola, A. J.; Anacker, D.; Donovan, D. M. Differentially conserved staphylococcal sh3b_5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. Gene 2009, 443, 32-41. [CrossRef] [PubMed]
16. Schmelcher, M.; Shabarova, T.; Eugster, M. R.; Eichenseher, F.; Tchang, V. S.; Banz, M.; Loessner, M. J. Rapid multiplex detection and differentiation of listeria cells by use of fluorescent phage endolysin cell wall binding domains. Appl. Environ. Microbiol. 2010, 76, 5745-5756. [CrossRef] [PubMed]
17. Schmelcher, M.; Tchang, V. S.; Loessner, M. J. Domain shuffling and module engineering of listeria phage endolysins for enhanced lytic activity and binding affinity. Microb. Biotechnol. 2011, 4, 651-662. [CrossRef] [PubMed]
18. Schuch, R.; Nelson, D.; Fischetti, V. A. A bacteriolytic agent that detects and kills bacillus anthracis. Nature 2002, 418, 884-889. [CrossRef] [PubMed]
19. Cheng, Q.; Nelson, D.; Zhu, S.; Fischetti, V. A. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 2005, 49, 111-117. [CrossRef] [PubMed]
20. Diez-Martinez, R.; de Paz, H. D.; Garcia-Fernandez, E.; Bustamante, N.; Euler, C. W.; Fischetti, V. A.; Menendez, M.; Garcia, P. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J. Antimicrob. Chemother. 2015, 70, 1763-1773. [CrossRef] [PubMed]
21. Singh, P. K.; Donovan, D. M.; Kumar, A. Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob. Agents Chemother. 2014, 58, 4621-4629. [CrossRef] [PubMed]
22. McCullers, J. A.; Karlstrom, A.; Iverson, A. R.; Loeffler, J. M.; Fischetti, V. A. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog. 2007, 3, e28. [CrossRef] [PubMed]
23. Mao, J.; Schmelcher, M.; Harty, W. J.; Foster-Frey, J.; Donovan, D. M. Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme. FEMS Microbiol. Lett. 2013, 342, 30-36. [CrossRef] [PubMed]
24. Schmelcher, M.; Korobova, O.; Schischkova, N.; Kiseleva, N.; Kopylov, P.; Pryamchuk, S.; Donovan, D. M.; Abaev, I. Staphylococcus haemolyticus prophage PhiSH2 endolysin relies on cysteine, histidine-dependent amidohydrolases/peptidases activity for lysis "from without". J. Biotechnol. 2012, 162, 289-298. [CrossRef] [PubMed]
25. Obeso, J. M.; Martinez, B.; Rodriguez, A.; Garcia, P. Lytic activity of the recombinant staphylococcal bacteriophage FH5 endolysin active against Staphylococcus aureus in milk. Int. J. Food Microbiol. 2008, 128, 212-218. [CrossRef] [PubMed]
26. Garcia, P.; Martinez, B.; Rodriguez, L.; Rodriguez, A. Synergy between the phage endolysin Lysh5 and nisin to kill Staphylococcus aureus in pasteurized milk. Int. J. Food Microbiol. 2010, 141, 151-155. [CrossRef] [PubMed]
27. Briers, Y.; Lavigne, R. Breaking barriers: Expansion of the use of endolysins as novel antibacterials against gram-negative bacteria. Future Microbiol. 2015, 10, 377-390. [CrossRef] [PubMed]
28. Roach, D. R.; Khatibi, P. A.; Bischoff, K. M.; Hughes, S. R.; Donovan, D. M. Bacteriophage-encoded lytic enzymes control growth of contaminating lactobacillus found in fuel ethanol fermentations. Biotechnol. Biofuels 2013, 6. [CrossRef] [PubMed]